IMMUNOTHERAPY DRUGS MARKET ANALYSIS

Immunotherapy Drugs Market Size and Trends

Global immunotherapy drugs market is estimated to be valued at USD 166.55 Bn in 2024 and is expected to reach USD 351.73 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 11.3% from 2024 to 2031.

To learn more about this report, Request sample copy

The immunotherapy drugs market is witnessing positive growth trends over the years. Immune checkpoint inhibitors, which help unleash the body's own immune response against cancer, have emerged as a major category of immunotherapy. Checkpoint inhibitor drugs such as Keytruda, Opdivo and Tecentriq are widely adopted drugs. Rising incidence of cancer cases globally and increasing preference for precision medicines are key factors boosting demand for immunotherapy drugs over the forecast period.

Rising awareness about cancer immunotherapy

With increasing incidence of various types of cancer worldwide, there is rising awareness among public as well as medical professionals about innovative treatment options. Cancer immunotherapy is gaining prominence as it utilizes body's own immune system to fight cancer in a novel way. Various advocacy groups are educating people about this option through awareness campaigns. These are highlighting how immunotherapy helps activate patient's own T cells to identify and destroy cancer cells in a targeted manner. This avoids non-specific killing of normal cells like other treatment options. The success stories showcased by advocacy groups and patients who benefited from immunotherapy are helping change perceptions. Where earlier surgery or chemo was the default option, now patients ask doctors about immunotherapy upfront. Medical conferences are dedicating special sessions to share research advances and real-world experiences with immunotherapy.

To learn more about this report, Request sample copy

Another important driver is the encouraging results seen with combining different immunotherapy drugs or combining immunotherapy with other treatment modalities. Early successes with checkpoint inhibitors led to focus on their potential to work even better when paired together or added to conventional therapies. Ongoing research is exploring diverse combination regimens tailored to individual cancer types and stages of disease. Some combinations show response rates much higher than any drug alone. These are also helping widen the pool of patients who can benefit. For instance, combining a PD-1 inhibitor with CTLA-4 antibody is giving durable responses in melanoma, lung and other cancers. Adding these to chemotherapy prior to surgery in early breast cancer patients improves pathologic response rates. Similarly, providing immunotherapy before or after radiation helps recruit immune cells to target radiation boosted tumor cells or residuals. The scope is also extending to accelerator drugs that can enhance effects of PD-1/PDL-1 inhibitors when given together.